All men should be screened for prostate cancer, at some point, but those who are most at risk for the condition might no longer need a biopsy and surgery under brand new guidelines from the National Institutes of Health and Care Excellence. Read the article here.
Magnetic resonance imaging (MRI) of the prostate may be used in many clinical scenarios, including primary screening, active surveillance, and in patients with a previous negative biopsy and rising PSA. Scott Eggener, MD, explains whether MRI is warranted in each of these situations and the benefits and challenges this technology presents. Read the article here.
Loyola Medicine is the first center in the Midwest to offer the first effective PET/CT scan for prostate cancer patients. The scan can detect the location and extent of cancer that has recurred after initial treatment and spread to other parts of the body. Prostate PET/CT scans can detect cancer earlier than either CT scans alone or MRI scans. Read the article here.
Robert K. Nam, MD, from the Sunnybrook Health Sciences Center in Toronto, and colleagues examined the feasibility of prostate MRI as the primary screening test for prostate cancer in a cohort of unselected men from the general population. All participants underwent prostate multiparametric MRI and random or targeted biopsies as well as prostate-specific antigen testing. Initial results showed that prostate MRI was better to predict prostate cancer than PSA. Read the article here.
A team of scientists led by researchers from Roswell Park Cancer Institute in Buffalo have demonstrated that photoacoustic imaging (PAI) may be an effective tool for more accurately viewing and monitoring prostate cancer. Photoacoustic imaging of enabled good discrimination between cells with and without the cancer marker, PSMA. Read the article here.